Business Combinations (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended					12 Months Ended
	Jun. 30, 2013	Jul. 01, 2012	Jun. 30, 2013	Jul. 01, 2012	Dec. 30, 2012	Mar. 31, 2013	Apr. 01, 2012	Jan. 01, 2012	Nov. 30, 2012 Human Health [Member] Haoyuan Biotech Co. [Member]	Dec. 30, 2012 Core Technology [Member] Human Health [Member] Haoyuan Biotech Co. [Member]
Business Acquisition [Line Items]
Cash paid to the shareholders									$ 38,000,000
Working capital adjustments									(2,729,000)
Additional contingent consideration	36,800,000		36,800,000						30,000,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value									1,900,000
Acquired Finite-lived Intangible Asset, Weighted Average Useful Life										8 years
Total transaction costs	100,000	100,000	100,000	300,000
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions					1 year
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 3,715,000	$ 7,315,000	$ 3,715,000	$ 7,315,000	$ 3,017,000	$ 2,727,000	$ 20,636,000	$ 20,298,000
Business Combination, Contingent Consideration Arrangements, Maximum Period			3 years
Business Combination, Contingent Consideration Arrangements, Description			Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. The earnout periods for each of these acquisitions do not exceed three years from the acquisition date.